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Dear editor 
It is with great interest that we read the recent article by De Francesco et al (1), who 
reported on chlamydia pneumoniae and mycoplasma pneumoniae co-infection in patients 
with COVID-19. Here, we report our experience with candidaemia co-infection with COVID-
19. An increased incidence of candidaemia has been noted in patients with COVID-19 and 
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although patient characteristics, investigations and antifungal therapies have been 
described (2), to our knowledge, compliance with candidaemia management bundles has 
not (3).   
Here, we present a retrospective review of candidaemias in adult patients (>17 
years) with PCR proven COVID-19 between 1st March 2020 - 31st May 2020 across six acute 
London hospitals. All yeasts isolated from blood cultures were identified by matrix assisted 
laser desorption/ionisation-time-of-flight (MALDI-TOF) mass spectroscopy (Bruker Daltonik 
GmbH, Bremen, Germany). Antifungal susceptibility testing was carried out using broth 
micro-dilution in accordance with EUCAST guidelines (4). An episode of candidaemia was 
defined as blood culture growth of any Candida species.  
Eleven patients with concurrent candidaemia and PCR-proven COVID-19 were 
identified during the study period; ten were male (90.9%), mean age 62 (33-77 years). 
Underlying comorbidities were predominantly cardiovascular (10/11). Two patients were 
immunosuppressed (see Table 1), but neutropenia was not identified.  
Ten patients (90.9%) were admitted to an intensive care unit (ICU) prior to their 
candidaemia diagnosis. Of the ICU patients (n=10), all were intubated and ventilated, had an 
intravascular and urinary catheter and received inotropes. The non-ICU patient also had a 
urinary catheter. Nine (90%) of the ICU patients received haemofiltration. None of the 
patients in our cohort received total parenteral nutrition. 
All eleven patients received broad-spectrum antibacterials. One patient received 
prior antifungal treatment in hospital with topical clotrimazole and oral terbinafine for a 
tinea infection.  
The average number of days from PCR-proven COVID-19 to candidaemia was 14.8 
days and from ICU admission to candidaemia, 15.5 days (range 6–24 days). Seven out of 
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eleven candidaemias (63.6%) were C.albicans, two (18.2%) C.parapsilosis, one (9.1%) C. 
glabrata and one (9.1%) C.dubliniensis. All isolates were fluconazole susceptible, except one 
(Candida glabrata), which showed intermediate susceptibility, although the patient was 
successfully treated with azole therapy through dose-optimisation. 
An echinocandin was commenced for ten patients, as per local guidelines, pending 
susceptibility testing. One patient died prior to blood culture positivity and treatment. Four 
out of ten (40%) patients were switched to fluconazole to complete treatment. In line with 
recommended practice (3) six out of eleven patients (54.5%) had repeat blood cultures 
within 48 hours of treatment, eight (72.7%) patients had an echocardiogram, but only one 
(9.1%) had fundoscopy. Serum (1-3)-β-D-glucan(BDG) testing was performed in 54.4% (6/11) 
of patients; three were positive(see Table 1). 
Intravascular catheters were removed for nine out of ten patients (90%), the last 
patient dying prior to candidaemia notification. Seven out of nine patients had line tips sent 
for culture; two were positive for yeasts. One line tip confirmed an identical Candida spp., 
and hence constituted a line infection, but no further identification was available for the 
second. 
Four patients had prior colonization with yeasts; one with the same species as their 
candidaemia, no further identification was available for the remaining three. Five patients 
were not colonized and two had an unknown status following transfer from other secondary 
care providers, developing candidaemia shortly after transfer.  
In concordance with Mastrangelo et al (1), there was a high 30-day mortality of 
54.4% (6/11) in our patient cohort. The four surviving patients (36.6%) were discharged; 
average total length of stay 58 days (range 31-78 days). One patient was stepped down after 
nine weeks in ICU but remained an inpatient until the end of our study period. 
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Given the high mortality rate, it is important to identify and address modifiable risk 
factors in an attempt to prevent the occurrence of candidaemia. Firstly, all our patients 
received broad-spectrum antibacterials, a recognized risk factor for candidaemia (5,6). A 
recent study from Hughes et al (7) demonstrated a low frequency (3.2%) of early bacterial 
co-infection in patients hospitalized with COVID-19, suggesting early broad-spectrum 
antibacterials may not be warranted. Hence, antimicrobial stewardship initiatives to review 
unnecessary antibacterial use remain important. 
Secondly, intravascular catheters are a well-recognised risk factor for candidaemia 
(5) and over 90% of our patients had these. The incidence of candidaemia observed 
warrants further consideration, and whilst not compared to pre-COVID-19 incidence (2), 
may potentially reflect pandemic unique challenges. Examples include increased ICU 
capacity, redeployment of less-experienced staff to ICU, challenges to aseptic technique 
with personal protective equipment (PPE), and patients requiring re-positioning to improve 
oxygenation, thus increasing possibility of line displacement/contamination. Improved 
aseptic intravascular catheter training focusing on PPE may be beneficial. 
In addition, although we were unable to identify urinary catheters as a source in our 
cohort, they are a recognized risk factor for candidaemia (6) and all patients in our cohort 
had these.   
One patient died prior to candidaemia notification. Time to blood culture positivity 
may be delayed, particularly for non-albicans candidaemias (8), and delay in treatment is 
known to increase mortality (9), therefore, non-culture-based diagnostics such as 
galactomannan antigen and BDG should be combine with clinical data to aid diagnosis (10).  
54.4% (n=6) of the patients were tested for BDG, and of those, 50% (n=3) were positive. 
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Although not possible to demonstrate in this patient cohort, an early positive BDG may 
herald invasive fungal infection, enabling timely initiation of empirical antifungal therapy.  
Guidelines for management of candidaemia recommend a care bundle, including 
repeat blood cultures at 48 hours, echocardiogram, and fundoscopy to identify 
disseminated infection. In our cohort, only 54.5 % (6/11) of patients had repeat blood 
cultures within 48 hours, 72.7 % (8/11) an echocardiogram and only 9.1% (1/11) 
fundoscopy. COVID-19 infection control concerns, patient positioning and PPE, with 
resultant challenges to ophthalmic examination, may account for the poor fundoscopy 
compliance, adding further weight to the need for COVID-19 specific practical training. 
 To conclude, during the ongoing COVID-19 pandemic it remains important to 
consider modifiable risk factors for candidaemia, non-culture based diagnositics to aid early 
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Clinical course  
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a: One patient received 9mg prednisolone once daily plus 500mg mycophenolate mofetil 
twice daily for myasthenia gravis A second patient received hydrocortisone 10mg/5mg/5mg 
for hypopituitarism. 
 
b: Positive results included values of 256 pg/ml, 154 pg/ml and 110 pg/ml 
 
Table 1: Characteristics of patients with concurrent COVID-19 and candidaemia. 
         
